Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.…
Pila Pharma deltar på konferens i Köln i nästa vecka (FinWire Smallcap)
Pila Pharma (STO: PILA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.570 SEK on 20 November 2026, down 32.0% over 52 weeks. Its 52-week range is 1.020 SEK to 2.500 SEK: the price is 37.2% below the high and 53.9% above the low.
Its market capitalisation is 71.72M SEK.
Pila Pharma reports return on equity of -116.1%.
It holds more cash than debt, a net cash position of 3.26M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 2.610 SEK is 66.2% above the current price.
No upcoming events tracked.